信隆健康：2025年前三季度净利润约-3014万元

Group 1 - The core viewpoint of the news is that Xilong Health reported its third-quarter performance, showing a revenue increase but a net loss for the period [1] - For the first three quarters of 2025, the company's revenue was approximately 864 million yuan, representing a year-on-year increase of 5.59% [1] - The net profit attributable to shareholders was a loss of approximately 30.14 million yuan, with basic earnings per share reflecting a loss of 0.082 yuan [1] Group 2 - As of the report, Xilong Health has a market capitalization of 2.6 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, amounting to 80 billion US dollars this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is experiencing a cooling in fundraising [2]